These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16640804)

  • 1. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program.
    Thomas SK; Fossella FV; Liu D; Schaerer R; Tsao AS; Kies MS; Pisters KM; Blumenschein GR; Glisson BS; Lee JJ; Herbst RS; Zinner RG
    Clin Lung Cancer; 2006 Mar; 7(5):326-31. PubMed ID: 16640804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America.
    Ho C; Murray N; Laskin J; Melosky B; Anderson H; Bebb G
    Lung Cancer; 2005 Aug; 49(2):225-31. PubMed ID: 15925429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study.
    Chang A; Parikh P; Thongprasert S; Tan EH; Perng RP; Ganzon D; Yang CH; Tsao CJ; Watkins C; Botwood N; Thatcher N
    J Thorac Oncol; 2006 Oct; 1(8):847-55. PubMed ID: 17409969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer.
    Yang CH; Shih JY; Chen KC; Yu CJ; Yang TY; Lin CP; Su WP; Gow CH; Hsu C; Chang GC; Yang PC
    Cancer; 2006 Oct; 107(8):1873-82. PubMed ID: 16989002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan: a prospective phase II study.
    Chen YM; Perng RP; Tsai CM
    J Chemother; 2005 Dec; 17(6):679-84. PubMed ID: 16433201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer.
    Yin YM; Geng YT; Shao YF; Hu XL; Li W; Shu YQ; Wang ZX
    J Exp Clin Cancer Res; 2010 Sep; 29(1):126. PubMed ID: 20843324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients.
    Chang GC; Tsai CM; Chen KC; Yu CJ; Shih JY; Yang TY; Lin CP; Hsu JY; Chiu CH; Perng RP; Yang PC; Yang CH
    J Thorac Oncol; 2006 Jul; 1(6):520-5. PubMed ID: 17409911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of gefitinib in the management of Asian patients with non-small cell lung cancer.
    Chang AY
    Expert Opin Investig Drugs; 2008 Mar; 17(3):401-11. PubMed ID: 18321238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future.
    Yang CH
    Lung Cancer; 2008 Jun; 60 Suppl 2():S23-30. PubMed ID: 18513581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients.
    Biaoxue R; Shuanying Y; Wei L; Wei Z; Zongjuan M
    Curr Med Res Opin; 2012 Oct; 28(10):1699-708. PubMed ID: 22978775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib for advanced non-small cell lung cancer.
    Sim EH; Yang IA; Wood-Baker R; Bowman RV; Fong KM
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD006847. PubMed ID: 29336009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer.
    Deng J; Fang WJ; Zhang XC; Wu DP; Fang HM; Chen J; Qian J; Mou HB; Chu BB; Xu N; Teng LS
    Med Oncol; 2012 Jun; 29(2):595-9. PubMed ID: 21399997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.
    Han SW; Kim TY; Lee KH; Hwang PG; Jeon YK; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ
    Lung Cancer; 2006 Nov; 54(2):201-7. PubMed ID: 16956694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
    Wu YL; Saijo N; Thongprasert S; Yang JC; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang JJ; Mok TS; Young H; Haddad V; Rukazenkov Y; Fukuoka M
    Lung Cancer; 2017 Feb; 104():119-125. PubMed ID: 28212993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
    Inoue A; Yoshida K; Morita S; Imamura F; Seto T; Okamoto I; Nakagawa K; Yamamoto N; Muto S; Fukuoka M
    Jpn J Clin Oncol; 2016 May; 46(5):462-7. PubMed ID: 26977054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania.
    Veronese ML; Algazy K; Bearn L; Eaby B; Alavi J; Evans T; Stevenson JP; Shults J
    Cancer Invest; 2005; 23(4):296-302. PubMed ID: 16100941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of gefitinib in non-small cell lung cancer: an Asian perspective.
    Jiang H
    Jpn J Clin Oncol; 2009 Mar; 39(3):137-50. PubMed ID: 19088154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.